Literature DB >> 22202043

Structure and function of the hematopoietic cancer niche: focus on chronic lymphocytic leukemia.

Jessi-F Fecteau1, Thomas J Kipps.   

Abstract

Chronic Lymphocytic Leukemia (CLL) is a B cell malignancy characterized by the accumulation of mature monoclonal CD5-positive B cells in the blood, secondary lymphoid tissues, and marrow. The infiltration of CLL cells in lymphoid tissues is a key element of disease pathogenesis. It is in such tissues that are found the microenvironments that provide CLL cells protection from spontaneous and/or drug-induced apoptosis. CLL cells actively shape their microenvironment by producing cytokines and chemokines, and by subverting normal accessory cells to promote leukemia-cell survival, proliferation, and escape from immune detection. In this review, we discuss how CLL cells disrupt the niches required for normal hematopoiesis or immune function and subvert normal cells in the microenvironment to support neoplastic cell growth and survival.

Entities:  

Mesh:

Year:  2012        PMID: 22202043      PMCID: PMC4114230          DOI: 10.2741/s251

Source DB:  PubMed          Journal:  Front Biosci (Schol Ed)        ISSN: 1945-0516


  116 in total

Review 1.  Role of the microenvironment in chronic lymphocytic leukaemia.

Authors:  Federico Caligaris-Cappio
Journal:  Br J Haematol       Date:  2003-11       Impact factor: 6.998

2.  Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.

Authors:  Zhi-Zhang Yang; Anne J Novak; Mary J Stenson; Thomas E Witzig; Stephen M Ansell
Journal:  Blood       Date:  2006-01-10       Impact factor: 22.113

3.  Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells.

Authors:  Irina Idler; Krzysztof Giannopoulos; Thorsten Zenz; Nupur Bhattacharya; Maria Nothing; Hartmut Döhner; Stephan Stilgenbauer; Daniel Mertens
Journal:  Br J Haematol       Date:  2009-11-30       Impact factor: 6.998

4.  CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells.

Authors:  T Vaisitti; S Aydin; D Rossi; F Cottino; L Bergui; G D'Arena; L Bonello; A L Horenstein; P Brennan; C Pepper; G Gaidano; F Malavasi; S Deaglio
Journal:  Leukemia       Date:  2010-03-11       Impact factor: 11.528

5.  Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1.

Authors:  T Nagasawa; S Hirota; K Tachibana; N Takakura; S Nishikawa; Y Kitamura; N Yoshida; H Kikutani; T Kishimoto
Journal:  Nature       Date:  1996-08-15       Impact factor: 49.962

6.  Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro.

Authors:  P Panayiotidis; D Jones; K Ganeshaguru; L Foroni; A V Hoffbrand
Journal:  Br J Haematol       Date:  1996-01       Impact factor: 6.998

7.  Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP.

Authors:  Antti Harjunpää; Minna Taskinen; Matti Nykter; Marja-Liisa Karjalainen-Lindsberg; Heidi Nyman; Outi Monni; Samuli Hemmer; Olli Yli-Harja; Sampsa Hautaniemi; Seppo Meri; Sirpa Leppä
Journal:  Br J Haematol       Date:  2006-08-22       Impact factor: 6.998

8.  Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.

Authors:  S Kitada; J M Zapata; M Andreeff; J C Reed
Journal:  Br J Haematol       Date:  1999-09       Impact factor: 6.998

9.  Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine.

Authors:  Marc Beyer; Matthias Kochanek; Kamruz Darabi; Alexey Popov; Markus Jensen; Elmar Endl; Percy A Knolle; Roman K Thomas; Michael von Bergwelt-Baildon; Svenja Debey; Michael Hallek; Joachim L Schultze
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

10.  MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration.

Authors:  Javier Redondo-Muñoz; Elizabeth Escobar-Díaz; Rafael Samaniego; María José Terol; José A García-Marco; Angeles García-Pardo
Journal:  Blood       Date:  2006-07-13       Impact factor: 22.113

View more
  14 in total

1.  Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways.

Authors:  Daniel J Medina; Lauri Goodell; John Glod; Céline Gélinas; Arnold B Rabson; Roger K Strair
Journal:  Haematologica       Date:  2012-02-27       Impact factor: 9.941

2.  Mechanistic Insights into CpG DNA and IL-15 Synergy in Promoting B Cell Chronic Lymphocytic Leukemia Clonal Expansion.

Authors:  Rashmi Gupta; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2018-08-01       Impact factor: 5.422

3.  Reduction of myeloid-derived suppressor cells and lymphoma growth by a natural triterpenoid.

Authors:  Faisal F Y Radwan; Azim Hossain; Jason M God; Nathan Leaphart; Michelle Elvington; Mitzi Nagarkatti; Stephen Tomlinson; Azizul Haque
Journal:  J Cell Biochem       Date:  2015-01       Impact factor: 4.429

4.  Chronic lymphocytic leukemia disease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model.

Authors:  Valeria Lascano; Marco Guadagnoli; Jan G Schot; Dieuwertje M Luijks; Jeroen E J Guikema; Katherine Cameron; Michael Hahne; Steven Pals; Erik Slinger; Thomas J Kipps; Marinus H J van Oers; Eric Eldering; Jan Paul Medema; Arnon P Kater
Journal:  Blood       Date:  2013-10-07       Impact factor: 22.113

5.  The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia.

Authors:  Davide Brusa; Sara Serra; Marta Coscia; Davide Rossi; Giovanni D'Arena; Luca Laurenti; Ozren Jaksic; Giorgio Fedele; Giorgio Inghirami; Gianluca Gaidano; Fabio Malavasi; Silvia Deaglio
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

6.  Treatment of chronic lymphocytic leukemia with bendamustine in an HIV-infected patient on antiretroviral therapy: a case report and review of the literature.

Authors:  Naoki Shimada; Koichiro Yuji; Nobuhiro Ohno; Tomohiko Koibuchi; Naoki Oyaizu; Kaoru Uchimaru; Arinobu Tojo
Journal:  Clin Case Rep       Date:  2015-04-22

7.  Guilty bystanders: nurse-like cells as a model of microenvironmental support for leukemic lymphocytes.

Authors:  Agata A Filip; Bogumiła Ciseł; Ewa Wąsik-Szczepanek
Journal:  Clin Exp Med       Date:  2013-12-12       Impact factor: 3.984

8.  Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells.

Authors:  Loris De Cecco; Matteo Capaia; Simona Zupo; Giovanna Cutrona; Serena Matis; Antonella Brizzolara; Anna Maria Orengo; Michela Croce; Edoardo Marchesi; Manlio Ferrarini; Silvana Canevari; Silvano Ferrini
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

9.  Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia.

Authors:  Ignacio Criado; Elena Blanco; Arancha Rodríguez-Caballero; Miguel Alcoceba; Teresa Contreras; María Laura Gutiérrez; Alfonso Romero; Paulino Fernández-Navarro; Marcos González; Fernando Solano; Carlos Gómez; Martín Pérez-Andrés; Jacques J M van Dongen; Julia Almeida; Alberto Orfao
Journal:  Leukemia       Date:  2018-06-21       Impact factor: 11.528

10.  Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.

Authors:  Ian W Flinn; Manish Patel; Yasuhiro Oki; Steven Horwitz; Francine F Foss; Kerstin Allen; Mark Douglas; Howard Stern; Jennifer Sweeney; Jahnavi Kharidia; Patrick Kelly; Virginia M Kelly; Brad Kahl
Journal:  Am J Hematol       Date:  2018-08-31       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.